Latest Bio-Reference Laboratories (BRLI) Headlines
Post# of 15
Posted On: 03/13/2014 6:12:32 AM
Latest Bio-Reference Laboratories (BRLI) Headlines
Myriad Stock Tumbles After Court Allows Rival To Sell
at Investor's Business Daily - Tue Mar 11, 10:18AM CDT
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for...
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Bio-Reference Labs Has Returned 15.8% Since SmarTrend Recommendation (BRLI)
Comtex SmarTrend(R) - Thu Mar 06, 11:13AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 months, Bio-Reference Labs has returned 15.75% as of today's recent price of $25.00.
Bio-Reference Laboratories (BRLI) Falls: Stock Goes Down 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:42AM CST
Bio-Reference Laboratories saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 5% on the day.
Bio-Reference Laboratories, Inc. Reports Revenue Growth Despite Reimbursement Pressure and Impactful Weather
GlobeNewswire - Tue Mar 04, 7:31AM CST
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announces record first quarter results for revenues. Except for per share data or where otherwise noted, numbers are in thousands.
Bio-Reference Labs Shares Down 13.4% Since SmarTrend's Sell Call (BRLI)
Comtex SmarTrend(R) - Thu Feb 27, 9:59AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 months, Bio-Reference Labs has returned 13.36% as of today's recent price of $25.71.
BioReference Laboratories, Inc. Announces Earnings Date for First Quarter Fiscal Year 2014
GlobeNewswire - Tue Feb 25, 9:25AM CST
BioReference Laboratories, Inc. (Nasdaq:BRLI) announced today it plans to issue earnings results for the first quarter 2014 before the open of market trading on Tuesday, March 4, 2014. The Company's earnings conference call is to take place the same day at 10:30 a.m. EST. The call will be hosted by Marc D. Grodman M.D., President and Chief Executive Officer.
Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019
M2 - Tue Feb 25, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/zt5xj4/clinical) has announced the addition of the "Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019" report to their offering. The clinical diagnostic tests performed by laboratories can be broadly classified into four major categories, namely, clinical chemistry, medical microbiology & cytology, human and tumour genetics and other esoteric tests. Ranging from routine blood and urine tests to high-end genetic analysis including fluorescence in situ hybridization (FISH), molecular expression testing etc., clinical laboratories offer numerous tests that help detect disease progression and abnormalities. The three major types of service providers in this market include hospital-based laboratories, clinic-based laboratories and stand-alone laboratories. The global market for clinical laboratory services is expected to record a CAGR of 5.8% during the forecast period of 2013 to 2019, to grow from a USD 162.71 billion market in 2012 to a USD 241.37 billion market in 2019. With the increasing incidence rates of debilitating conditions such as cancer, diabetes and infectious diseases, the number of patients that will opt for such tests will continue to increase in the future and thereby increase the demand for these services. Moreover, the percentage of aged population in the U.S. is expected to grow to an estimated 20% by 2030. Such a large population of elderly people in the U.S. alone will lead to high testing volumes for clinical laboratories. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/zt5xj4/clinical
Downtrend Call Working As Bio-Reference Labs Stock Falls 11.9% (BRLI)
Comtex SmarTrend(R) - Mon Feb 10, 9:33AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 11.88% as of today's recent price of $26.15.
New Research Centre to Help Injured, Ill and Disabled Workers Stay in Job Market
Marketwire Canada - Tue Feb 04, 3:00AM CST
Vancouver-based Krystal Johnston, 29, has carpal tunnel syndrome. Two surgeries, one on each wrist, failed to fix the loss of feeling in her hands and arms.
Bio-Reference Labs Down 17.2% Since SmarTrend Downtrend Call (BRLI)
Comtex SmarTrend(R) - Tue Jan 14, 5:27PM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 17.20% as of today's recent price of $24.57.
Quest Diagnostics Inc.: Does This Unloved Company Deserve Your Attention
Cory Renauer, The Motley Fool - Motley Fool - Thu Jan 09, 12:19PM CST
After nearly two years of flat to falling revenue, it's just plain difficult for Quest Diagnostics to get any positive attention, especially with the black cloud of reimbursement uncertainty hanging over its industry. To end the year, shares of...
MYGN Faces Payment Cuts, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 2:20PM CST
Shares of Myriad Genetics fell following the announcement by CMS to reduce reimbursement rates on the former's BRACAnalysis test.
Myriad Price Cut Reflects Changing Gene-Test Industry
at Investor's Business Daily - Fri Jan 03, 4:25PM CST
The genetic-testing industry has come under the microscope again after Myriad Genetics' breast-cancer gene test got a big reimbursement cut from the federal government, adding pressure to a field whose 2014 outlook is cloudy. On Dec. 27, the Center...
Myriad Hit By Downgrades After Reimbursement Cut
at Investor's Business Daily - Mon Dec 30, 10:09AM CST
Myriad Genetics (MYGN) was hit by multiple analyst downgrades Monday, and a 16% plunge on the stock market today, after the Center for Medicare & Medicaid Services confirmed over the weekend that it's cutting reimbursement on Myriad's genetic tests...
Stock Price Movements, Financial Results, Conference Call Schedules, and Upcoming Presentations - Research Report on Charles River, The Medicines Company, Bio-Reference, HeartWare, and Haemonetics
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Charles River Laboratories (NYSE: CRL), The Medicines Company (NASDAQ: MDCO), Bio-Reference Laboratories Inc. (NASDAQ: BRLI), HeartWare International Inc. (NASDAQ: HTWR) and Haemonetics Corporation (NYSE: HAE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
14.1% Return Seen to Date on SmarTrend Bio-Reference Labs Call (BRLI)
Comtex SmarTrend(R) - Fri Dec 20, 9:24AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 weeks, Bio-Reference Labs has returned 14.07% as of today's recent price of $25.50.
Company news for December 20, 2013 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 8:06AM CST
Companies in the News are: ACN, ATU, BRLI, CAG
Global Clinical Laboratory Services Market Report 2013 - 2019
M2 - Fri Dec 20, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/vbxt5s/clinical) has announced the addition of the "Global Clinical Laboratory Services Market Report 2013 - 2019" report to their offering. The report covers the global clinical laboratory services market based on the various categories of tests conducted by laboratories, including clinical chemistry, medical microbiology & cytology, human & tumor genetics and other esoteric tests. The market is also segmented by service providers such as clinic-based, hospital-based and stand-alone laboratories. Geographically, the clinical laboratory services market has been divided into North America, Europe, Asia-Pacific and Rest of the World. The report provides market sizes and forecasts for each segment, sub-segment and geographic region, for 2011-2019 in terms of USD million, with 2012 as the base year. The CAGR % of each market segment, for the forecast period 2013 to 2019, has also been provided. The market overview section of the report presents an elaborate qualitative analysis of the market dynamics, based on factors like drivers, restraints and opportunities. Porter's five force analysis and market attractiveness analysis by geography for the global clinical laboratory services market has also been provided. Key Topics Covered: 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 List of Abbreviations 2 Executive Summary Chapter 3 Market Overview 3.1 Introduction 3.2 Population & Disease Incidence Rate Statistics 3.3 Market Drivers 3.4 Market Restraints 3.5 Market Opportunities 3.6 Porter's Five Forces Analysis: Global Clinical Laboratory Services Market 3.7 Market Attractiveness Analysis: Global Clinical Laboratory Services Market, By Geography, 2012 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 6.1 Overview 6.2 North America 6.3 Europe 6.4 Asia-Pacific 6.5 Rest Of The World (Row) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/vbxt5s/clinical
Myriad Stock Tumbles After Court Allows Rival To Sell
at Investor's Business Daily - Tue Mar 11, 10:18AM CDT
Myriad Genetics (MYGN) stock tumbled in early trading on the stock market today after a court late Monday denied it a preliminary injunction against a rival. Myriad has been trying to stop the entry of rival versions of its BRACAnalysis test for...
2014 Clinical Laboratory Services Global Strategic Business Report - Despite Challenges, Emerging Markets Provide Growth Opportunities
M2 - Tue Mar 11, 6:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tt3zfb/clinical) has announced the addition of the "Clinical Laboratory Services - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Clinical Laboratory Services in US$ Million by the following Product Segments: Hospital-Based Laboratories, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. COMPETITIVE LANDSCAPE 3. CLINICAL LABORATORY SERVICES - AN INTRODUCTION 4. PRODUCT INNOVATIONS/INTRODUCTIONS - Genomic Health Launches Oncotype DX Prostate Cancer Test - Clarient Rolls Out Next-Generation Sequencing Assay - SilverStaff Clinical Laboratories to Provide BGM Galectin-3® Test of BG Medicine - Quest Diagnostics Unveils Dementia Clinical Diagnostic Panel - Psychemedics Unveils Hair Alcohol Test - Prometheus Laboratories Introduces PROMETHEUS® Anser ADA - NeoGenomics Launches Clinical Molecular Tests for MDS - LipoScience Introduces Vantera Clinical Analyzer for Cardiovascular Disease Management - Atherotech Diagnostics Lab Introduces AspirinWorks® Test - GeneDx to Introduce Comprehensive Genetic Tests Suite for Ovarian and Breast Cancers - Enzo Clinical Labs Collaborates with Oncimmune to Launch Novel Diagnostic Test - Myriad RBM Introduces Oncology® v. 2.0 Test - NeoGenomics Introduces NeoSITE Barrett's Esophagus FISH Test - diaDexus Introduces CE marked PLAC Test for Lp-PLA(2) Activity 5. RECENT INDUSTRY ACTIVITY 6. FOCUS ON SELECT PLAYERS 7. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles164 companies including many key and niche players such as: - ADICON Clinical Laboratories - ARUP Laboratories - Asuragen - Atherotech Diagnostics Lab - Bio-Reference Laboratories - Bioscientia Institut f?r Medizinische Diagnostik - Clarient - DaVita - Enzo Clinical Labs - Gaoxin - Da an Health Investment - Gamma-Dynacare Medical Laboratories - Genoptix Medical Laboratory - Genova Diagnostics - Kingmed Diagnostics - Healthscope - Laboratory Corporation of America - Labco - Mayo Medical Laboratories - Myriad Genetic - Pathology - Prometheus Laboratories - Quest Diagnostics) - Sonic Healthcare - American Esoteric Laboratories - Spectra Laboratories - Thyrocare Technologies - The National Health Laboratory Service - Unilabs For more information visit http://www.researchandmarkets.com/research/tt3zfb/clinical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Bio-Reference Labs Has Returned 15.8% Since SmarTrend Recommendation (BRLI)
Comtex SmarTrend(R) - Thu Mar 06, 11:13AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 months, Bio-Reference Labs has returned 15.75% as of today's recent price of $25.00.
Bio-Reference Laboratories (BRLI) Falls: Stock Goes Down 5.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:42AM CST
Bio-Reference Laboratories saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell over 5% on the day.
Bio-Reference Laboratories, Inc. Reports Revenue Growth Despite Reimbursement Pressure and Impactful Weather
GlobeNewswire - Tue Mar 04, 7:31AM CST
Bio-Reference Laboratories, Inc. (Nasdaq:BRLI) announces record first quarter results for revenues. Except for per share data or where otherwise noted, numbers are in thousands.
Bio-Reference Labs Shares Down 13.4% Since SmarTrend's Sell Call (BRLI)
Comtex SmarTrend(R) - Thu Feb 27, 9:59AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 months, Bio-Reference Labs has returned 13.36% as of today's recent price of $25.71.
BioReference Laboratories, Inc. Announces Earnings Date for First Quarter Fiscal Year 2014
GlobeNewswire - Tue Feb 25, 9:25AM CST
BioReference Laboratories, Inc. (Nasdaq:BRLI) announced today it plans to issue earnings results for the first quarter 2014 before the open of market trading on Tuesday, March 4, 2014. The Company's earnings conference call is to take place the same day at 10:30 a.m. EST. The call will be hosted by Marc D. Grodman M.D., President and Chief Executive Officer.
Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019
M2 - Tue Feb 25, 5:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/zt5xj4/clinical) has announced the addition of the "Concise Analysis of the International Clinical Laboratory Services Market - Forecast to 2019" report to their offering. The clinical diagnostic tests performed by laboratories can be broadly classified into four major categories, namely, clinical chemistry, medical microbiology & cytology, human and tumour genetics and other esoteric tests. Ranging from routine blood and urine tests to high-end genetic analysis including fluorescence in situ hybridization (FISH), molecular expression testing etc., clinical laboratories offer numerous tests that help detect disease progression and abnormalities. The three major types of service providers in this market include hospital-based laboratories, clinic-based laboratories and stand-alone laboratories. The global market for clinical laboratory services is expected to record a CAGR of 5.8% during the forecast period of 2013 to 2019, to grow from a USD 162.71 billion market in 2012 to a USD 241.37 billion market in 2019. With the increasing incidence rates of debilitating conditions such as cancer, diabetes and infectious diseases, the number of patients that will opt for such tests will continue to increase in the future and thereby increase the demand for these services. Moreover, the percentage of aged population in the U.S. is expected to grow to an estimated 20% by 2030. Such a large population of elderly people in the U.S. alone will lead to high testing volumes for clinical laboratories. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/zt5xj4/clinical
Downtrend Call Working As Bio-Reference Labs Stock Falls 11.9% (BRLI)
Comtex SmarTrend(R) - Mon Feb 10, 9:33AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 11.88% as of today's recent price of $26.15.
New Research Centre to Help Injured, Ill and Disabled Workers Stay in Job Market
Marketwire Canada - Tue Feb 04, 3:00AM CST
Vancouver-based Krystal Johnston, 29, has carpal tunnel syndrome. Two surgeries, one on each wrist, failed to fix the loss of feeling in her hands and arms.
Bio-Reference Labs Down 17.2% Since SmarTrend Downtrend Call (BRLI)
Comtex SmarTrend(R) - Tue Jan 14, 5:27PM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 2 months, Bio-Reference Labs has returned 17.20% as of today's recent price of $24.57.
Quest Diagnostics Inc.: Does This Unloved Company Deserve Your Attention
Cory Renauer, The Motley Fool - Motley Fool - Thu Jan 09, 12:19PM CST
After nearly two years of flat to falling revenue, it's just plain difficult for Quest Diagnostics to get any positive attention, especially with the black cloud of reimbursement uncertainty hanging over its industry. To end the year, shares of...
MYGN Faces Payment Cuts, Shares Fall - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 06, 2:20PM CST
Shares of Myriad Genetics fell following the announcement by CMS to reduce reimbursement rates on the former's BRACAnalysis test.
Myriad Price Cut Reflects Changing Gene-Test Industry
at Investor's Business Daily - Fri Jan 03, 4:25PM CST
The genetic-testing industry has come under the microscope again after Myriad Genetics' breast-cancer gene test got a big reimbursement cut from the federal government, adding pressure to a field whose 2014 outlook is cloudy. On Dec. 27, the Center...
Myriad Hit By Downgrades After Reimbursement Cut
at Investor's Business Daily - Mon Dec 30, 10:09AM CST
Myriad Genetics (MYGN) was hit by multiple analyst downgrades Monday, and a 16% plunge on the stock market today, after the Center for Medicare & Medicaid Services confirmed over the weekend that it's cutting reimbursement on Myriad's genetic tests...
Stock Price Movements, Financial Results, Conference Call Schedules, and Upcoming Presentations - Research Report on Charles River, The Medicines Company, Bio-Reference, HeartWare, and Haemonetics
PR Newswire - Wed Dec 25, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Charles River Laboratories (NYSE: CRL), The Medicines Company (NASDAQ: MDCO), Bio-Reference Laboratories Inc. (NASDAQ: BRLI), HeartWare International Inc. (NASDAQ: HTWR) and Haemonetics Corporation (NYSE: HAE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
14.1% Return Seen to Date on SmarTrend Bio-Reference Labs Call (BRLI)
Comtex SmarTrend(R) - Fri Dec 20, 9:24AM CST
SmarTrend identified a Downtrend for Bio-Reference Labs (NASDAQ:BRLI) on November 29th, 2013 at $29.68. In approximately 3 weeks, Bio-Reference Labs has returned 14.07% as of today's recent price of $25.50.
Company news for December 20, 2013 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Fri Dec 20, 8:06AM CST
Companies in the News are: ACN, ATU, BRLI, CAG
Global Clinical Laboratory Services Market Report 2013 - 2019
M2 - Fri Dec 20, 6:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/vbxt5s/clinical) has announced the addition of the "Global Clinical Laboratory Services Market Report 2013 - 2019" report to their offering. The report covers the global clinical laboratory services market based on the various categories of tests conducted by laboratories, including clinical chemistry, medical microbiology & cytology, human & tumor genetics and other esoteric tests. The market is also segmented by service providers such as clinic-based, hospital-based and stand-alone laboratories. Geographically, the clinical laboratory services market has been divided into North America, Europe, Asia-Pacific and Rest of the World. The report provides market sizes and forecasts for each segment, sub-segment and geographic region, for 2011-2019 in terms of USD million, with 2012 as the base year. The CAGR % of each market segment, for the forecast period 2013 to 2019, has also been provided. The market overview section of the report presents an elaborate qualitative analysis of the market dynamics, based on factors like drivers, restraints and opportunities. Porter's five force analysis and market attractiveness analysis by geography for the global clinical laboratory services market has also been provided. Key Topics Covered: 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 List of Abbreviations 2 Executive Summary Chapter 3 Market Overview 3.1 Introduction 3.2 Population & Disease Incidence Rate Statistics 3.3 Market Drivers 3.4 Market Restraints 3.5 Market Opportunities 3.6 Porter's Five Forces Analysis: Global Clinical Laboratory Services Market 3.7 Market Attractiveness Analysis: Global Clinical Laboratory Services Market, By Geography, 2012 4 Global Clinical Laboratory Services Market, By Test Type, 2011 - 2019 (USD Billion) 5 Global Clinical Laboratory Services Market, By Service Provider, 2011 - 2019 (USD Billion) 6 Global Clinical Laboratory Services Market, By Geography, 2011 - 2019 (USD Billion) 6.1 Overview 6.2 North America 6.3 Europe 6.4 Asia-Pacific 6.5 Rest Of The World (Row) 7 Competitive Landscape 8 Recommendations 9 Company Profiles Companies Mentioned: - ARUP Laboratories - Abbott Laboratories - Bio-Reference Laboratories - Bioscientia Healthcare - Charles River Laboratories - Genoptix Medical Laboratory - Healthscope Ltd - Labco SA - Laboratory Corporation Of America Holdings (Labcorp) - Quest Diagnostics, Inc - Sonic Healthcare Limited - Spectra Laboratories For more information visit http://www.researchandmarkets.com/research/vbxt5s/clinical
(0)
(0)BioReference Laboratories Inc. (BRLI) Stock Research Links
Scroll down for more posts ▼